NMDA subunit 2B-selective negative allosteric modulator satoprodil (BI 1569912) as mono- and adjunctive therapy in patients with major depressive disorder: results from two phase 2 randomized, controlled trials.

BI 1569912 - Boehringer Ingelheim

http://www.ncbi.nlm.nih.gov/pubmed/42701110

Alla Feldbarg; Andreas Scholz; Brittney Starling; Elan A Cohen; Franco De Crescenzo; Gerard Sanacora; J Corey Fowler; Koichiro Watanabe; Rainer-Georg Goeldner; Sigurd D Süssmuth

Sep 6, 2026